Drug–Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy
article
OA: closed
CC0
⤵ 3 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist 2017
- Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix 2008
- Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment 2018
Cited by (3)
- Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women 2021
- Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids 2022
- Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Product: Phase 1 Results in Healthy Pre- and Postmenopausal Women 2024
References (27)
- Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment via openalex
- Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix via openalex
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
- W2041408953 via openalex
- W2045466762 via openalex
- W2052239036 via openalex
- W2076404033 via openalex
- W2079582849 via openalex
- W2084804973 via openalex
- W2088497136 via openalex
- W2186501044 via openalex
- W2574859291 via openalex
- W2595206985 via openalex
- W2602082991 via openalex
- W2610244466 via openalex
- W2624381351 via openalex
- W2727479394 via openalex
- W2750835876 via openalex
- W2762962267 via openalex
- W2765546885 via openalex
- W2896492055 via openalex
- W2986356381 via openalex
- W2990363083 via openalex
- W1964912441 via openalex
- W3002354512 via openalex
- W1967044786 via openalex
- W1996048503 via openalex
Cited by (3)
- Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Product: Phase 1 Results in Healthy Pre- and Postmenopausal Women 2024
- Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids 2022
- Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women 2021
Source provenance
- europepmc
- last seen: 2026-06-12T06:13:51.797165+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:21:53.586419+00:00
License: CC0
· commercial use OK